Incyte earns $19M milestone from Lilly

Wilmington, DE-based Incyte says that it earned a rich $19 million milestone from Eli Lilly after the pharma company launched the Phase IIb study of the rheumatoid arthritis drug INCB28050. Lilly inked a licensing pact covering Incyte's oral JAK1 and JAK2 inhibitor. The compound will now be referred to as LY3009104. Incyte release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.